RNAGADE
Dead / Abandoned — Abandoned — no statement of use filed (as of 15 Oct 2025)
What this means for you
This application is over — abandoned 15 Oct 2025. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 90545040
- Mark type
- Stylized text
- Filed
- 24 Feb 2021
- Published for opposition
- 14 Mar 2023
- Abandoned
- 15 Oct 2025
- Attorney of record
- Jonathan M. Gelchinsky
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations and substances, namely, RNA and DNA therapeutics for the treatment of infectious diseases, blood disorders, sepsis, alopecia, and cognitive disorders; pharmaceutical preparations, namely, RNA and DNA therapeutics for the prevention of osteoporosis; pharmaceutical preparations, namely, RNA and DNA therapeutics for the prevention of cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders, and reproductive disorders; pharmaceutical preparations, namely, RNA and DNA therapeutics for the treatment of immune system related diseases and disorders; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations, namely, RNA and DNA therapeutics for the treatment of viral infections; pharmaceutical preparations, namely, RNA and DNA therapeutics for the treatment of cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders, and reproductive disorders; pharmaceutical preparations, namely, RNA and DNA therapeutics for treating diabetes; pharmaceutical preparations, namely, RNA and DNA therapeutics for use in chemotherapy; pharmaceutical preparations, namely, RNA and DNA therapeutics for cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders, and reproductive disorders; pharmaceutical preparations, namely, antivirals; therapeutic pharmaceuticals, namely, RNA and DNA therapeutics for the treatment of cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders, and reproductive disorders; vaccine preparations, namely, RNA and DNA vaccine preparations; vaccines, namely, RNA and DNA vaccines; anti-epileptic pharmaceutical preparations; human vaccine preparations, namely, RNA and DNA vaccine preparations; medical preparations for the treatment of cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders, and reproductive disorders; medicinal preparations for the treatment of infectious diseases and for use in oncology; mixed biological preparations, namely, RNA and DNA therapeutics for the prevention and treatment of infectious diseases; pharmaceutical preparations, namely, RNA and DNA therapeutics for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; pharmaceutical preparations for the treatment of viral diseases; pharmaceutical products, namely, RNA and DNA therapeutics for the treatment of joint disease; pharmaceutical products, namely, RNA and DNA therapeutics for the treatment of viral and infectious diseases, for the treatment of cancer; therapeutic vaccines, namely, RNA and DNA therapeutics; all of the foregoing excluding medicinal dietary and nutritional supplements
Owner
- Renagade Therapeutics LLC, Watertown, MA, US
- Renagade Therapeutics LLC, Cambridge, MA, US
Prosecution history
- 15 Oct 2025 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 15 Oct 2025 — ABANDONMENT - NO USE STATEMENT FILED
- 24 Oct 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 24 Oct 2024 — SOU EXTENSION 3 GRANTED
- 24 Oct 2024 — SOU EXTENSION 3 FILED
- 24 Oct 2024 — SOU TEAS EXTENSION RECEIVED
- 04 Oct 2024 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 04 Oct 2024 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 04 Oct 2024 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 04 Oct 2024 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
- 04 Oct 2024 — TEAS CHANGE OF OWNER ADDRESS RECEIVED
- 10 Apr 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 09 Apr 2024 — SOU EXTENSION 2 GRANTED
- 09 Apr 2024 — SOU EXTENSION 2 FILED
- 09 Apr 2024 — SOU TEAS EXTENSION RECEIVED